HS-SY-II Xenograft Model Overview
The HS-SY-II xenograft model is derived from a human synovial sarcoma (SS) cell line, HS-SY-II, which was established from a primary tumor of a patient diagnosed with synovial sarcoma, a rare and aggressive soft tissue sarcoma. Synovial sarcoma primarily affects adolescents and young adults, typically presenting in the limbs, and is known for its high metastatic potential, frequent recurrence, and resistance to conventional chemotherapy. The HS-SY-II xenograft model closely mimics these features and is highly valuable for studying the biology of synovial sarcoma, its metastatic behavior, and therapeutic resistance. This model is extensively used in preclinical research to evaluate novel therapeutic strategies, including chemotherapy, targeted therapies, and immunotherapies for treating synovial sarcoma.
Request a Custom Quote for HS-SY-II Xenograft ModelBiological and Molecular Characteristics
HS-SY-II cells are characterized by their mesenchymal origin and the expression of both epithelial and mesenchymal markers. The model is particularly useful for studying the biology of synovial sarcoma, which is often associated with the SS18-SSX fusion gene, a chromosomal translocation that results in the production of a fusion protein that plays a critical role in tumor initiation and progression. The HS-SY-II cells express this SS18-SSX fusion gene, making it an ideal model for investigating the molecular mechanisms underlying synovial sarcoma. Additionally, HS-SY-II cells show activation of the PI3K/AKT and MAPK/ERK pathways, which are involved in tumor survival, proliferation, and metastasis. These molecular features make the HS-SY-II xenograft model particularly relevant for testing therapies aimed at inhibiting these pathways and targeting the SS18-SSX fusion protein.
| Marker | Expression Level | Function |
|---|---|---|
| SS18-SSX Fusion | Present | Oncogene fusion responsible for tumorigenesis |
| Cytokeratin | High | Epithelial cell marker |
| Vimentin | High | Mesenchymal marker, involved in tumor invasion |
| PI3K/AKT pathway | Dysregulated | Promotes cell survival and proliferation |
In Vivo Model Development and Tumorigenicity
The HS-SY-II xenograft model is typically established by implanting HS-SY-II cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Upon implantation, the cells form solid tumors that replicate the key features of human synovial sarcoma, including high cellularity, biphasic tumor structure (epithelial and mesenchymal), and significant vascularization. The tumors also demonstrate areas of necrosis, indicative of rapid tumor growth. HS-SY-II xenografts are widely used to evaluate chemotherapy agents such as doxorubicin, ifosfamide, and cisplatin, which are commonly used in the treatment of soft tissue sarcomas, including synovial sarcoma.
In addition to subcutaneous implantation, orthotopic models of HS-SY-II can be established by implanting the cells into the synovial tissues or soft tissues of immunocompromised mice. This orthotopic model more accurately mimics the natural site of tumor growth, allowing for the study of local invasion, metastatic spread, and the effects of treatment on the tumor microenvironment. The ability of HS-SY-II cells to metastasize to distant organs, particularly the lungs and lymph nodes, makes this model highly valuable for studying the metastatic behavior of synovial sarcoma and for evaluating therapies aimed at preventing or treating metastasis.
Request a Custom Quote for HS-SY-II Xenograft ModelHistopathology and Immunohistochemical Profile
Histopathological examination of HS-SY-II xenografts reveals the characteristic biphasic pattern of synovial sarcoma, with both epithelial and mesenchymal components present. The tumors show glandular-like structures (epithelial component) and spindle cells (mesenchymal component). Immunohistochemical staining of HS-SY-II xenografts demonstrates strong expression of epithelial markers such as cytokeratins and mesenchymal markers like vimentin, confirming the biphasic nature of the tumor. Additionally, the presence of the SS18-SSX fusion gene can be detected using specific probes, which plays a critical role in tumor development and progression. High levels of phosphorylated AKT are observed in the tumors, indicating the activation of the PI3K/AKT pathway, which supports tumor cell survival and resistance to chemotherapy. CD31 staining reveals significant angiogenesis within the tumors, reflecting the importance of blood vessel formation in sustaining tumor growth.
Preclinical Applications and Drug Response
The HS-SY-II xenograft model is widely used to evaluate the efficacy of various therapeutic agents for synovial sarcoma. The model is particularly useful for testing chemotherapy agents such as doxorubicin, ifosfamide, and cisplatin, which are standard treatments for soft tissue sarcomas, including synovial sarcoma. Given the model’s potential for developing resistance to chemotherapy, it is highly valuable for studying chemotherapy resistance mechanisms and for testing new agents aimed at overcoming these challenges. The model is also highly relevant for evaluating targeted therapies, particularly those aimed at inhibiting the SS18-SSX fusion protein and modulating dysregulated pathways such as PI3K/AKT and MAPK/ERK.
In addition to chemotherapy and targeted therapies, the HS-SY-II xenograft model is increasingly used to evaluate the potential of immunotherapies, including immune checkpoint inhibitors and monoclonal antibodies targeting tumor-specific antigens. The model’s ability to replicate key features of synovial sarcoma, including its aggressive growth, biphasic tumor structure, and metastatic potential, makes it an ideal system for studying new treatment strategies. Furthermore, the ability of HS-SY-II tumors to metastasize to the lungs provides an excellent opportunity to evaluate therapies aimed at preventing or treating metastatic disease, which is a critical challenge in synovial sarcoma treatment.
Request This Model
To request the HS-SY-II xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for HS-SY-II Xenograft Model